Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

MicroRNA biomarkers in whole blood for detection of pancreatic cancer

This week's issue of the Journal of the American Medical Association identified panels of microRNAs for use in diagnosis of pancreatic cancer compared with the cancer antigen 19-9.

News image

Biomarkers for the early diagnosis of patients with pancreatic cancer are needed to improve prognosis.

Dr Nicolai Schultz and colleagues from Denmark and colleagues described differences in microRNA expression in whole blood between patients with pancreatic cancer, chronic pancreatitis, and healthy participants.

The research team identified panels of microRNAs for use in diagnosis of pancreatic cancer compared with the cancer antigen 19-9 (CA19-9).

The team performed a case-control study that included 409 patients with pancreatic cancer, and 25 with chronic pancreatitis who had been included prospectively in the Danish BIOPAC (Biomarkers in Patients with Pancreatic Cancer) study (July 2008-October 2012) plus 312 blood donors as healthy participants.

The microRNA expressions in pretreatment whole blood RNA samples were collected and analyzed in 3 randomly determined subcohorts.

38 microRNAs in whole blood were significantly dysregulated in patients
Journal of the American Medical Association

The discovery cohort included 143 patients with pancreatic cancer, 18 patients with chronic pancreatitis, and 69 healthy participants.

The training cohort included 180 patients with pancreatic cancer, 1 patient with chronic pancreatitis, and 199 healthy participants.

The validation cohort involved 86 patients with pancreatic cancer, 7 patients with chronic pancreatitis, and 44 healthy participants.

The team screended 754 microRNAs in the discovery cohort, and 38 microRNAs in the training cohort, and 13 microRNAs in the validation cohort.

The research team's main outcomes included identification of microRNA panels (classifiers) for diagnosing pancreatic cancer.

The discovery cohort demonstrated that 38 microRNAs in whole blood were significantly dysregulated in patients with pancreatic cancer compared with controls.

The team tested these microRNAs in the training cohort, and 2 diagnostic panels were constructed comprising 4 microRNAs in index I, and 10 in index II.

The test characteristics for the training cohort were index I area under the curve (AUC) of 0.86, sensitivity of 0.85, and specificity of 0.64.

The values for index II were an AUC of 0.93, sensitivity of 0.85, and specificity of 0.85.

The team found that for CA19-9, the AUC was 0.90, with a sensitivity of 0.86, and specificity of 0.99.

Performances were strengthened in the validation cohort by combining panels and CA19-9.

Compared with CA19-9 alone, the AUC for the combination of index I and CA19-9 was significantly higher.

The researchers found that the performance of the panels in patients with stage IA-IIB pancreatic cancer was index I AUC of 0.80.

Index I with CA19-9 had an AUC of 0.83; index II had an AUC of 0.91, and index II with CA19-9 had an AUC of 0.91.

Dr Schultz's team commented, "This study identified 2 diagnostic panels based on microRNA expression in whole blood with the potential to distinguish patients with pancreatic cancer from healthy controls."

"Further research is necessary to understand whether these have clinical implications for early detection of pancreatic cancer and how much this information adds to serum CA19-9."

JAMA 2014: 311(4)
23 January 2014

Go to top of page Email this page Email this page to a colleague

 23 July 2014

Advanced search
 23 July 2014 
C-section and IBD risk
 23 July 2014 
Sofosbuvir and ribavirin for Hep C
 23 July 2014 
Early corticosteroids after the diagnosis of ulcerative colitis
 22 July 2014 
Alcohol and colorectal adenoma risk
 22 July 2014 
Cognitive behavioral therapy in IBS
 22 July 2014 
Thromboembolism in IBD
 21 July 2014 
Mortality in IBD
 21 July 2014 
Stents to prevent post-ERCP pancreatitis
 21 July 2014 
Psychometric validation of IBS symptom severity
 18 July 2014 
ERCP with overtube-assisted enteroscopy
 18 July 2014 
Treatment of enteropancreatic neuroendocrine tumors
 18 July 2014 
Ulcer complications and dyspeptic symptoms
 17 July 2014 
Small intestinal permeability in diarrhea predominant IBS
 17 July 2014 
Treatment of H. pylori
 17 July 2014 
Ultrasound for diagnosis of gastric varices
 16 July 2014 
Mortality after colectomy in IBD
 16 July 2014 
Esophageal cancer missed at endoscopy
 16 July 2014 
Screening for Hepatitis B
 15 July 2014 
Diagnosing diverticulitis
 15 July 2014 
Variation in management decisions for colorectal cancer
 15 July 2014 
Muscle cramps in cirrhosis
 14 July 2014 
Predicting the course of ulcerative colitis
 14 July 2014 
Choice in colorectal cancer screening tests
 14 July 2014 
Adhesions in abdominal surgery
 11 July 2014 
Temporal evolution of antidrug antibodies in IBD
 11 July 2014 
Atopy and functional gastrointestinal disorders
 11 July 2014 
Fecal microbiota transplant for C. diff
 10 July 2014 
Acid-suppressive medications and cancer risk in Barrett's
 10 July 2014 
Personalized medicine in the management of IBD
 10 July 2014 
Pregnancy outcome in anti-TNF treated women with IBD
 09 July 2014 
Quality of care provided to patients with varices
 09 July 2014 
Eosinophilic esophagitis and celiac disease
 09 July 2014 
Diagnosis and management of adult celiac disease
 08 July 2014 
Screening for Hep B
 08 July 2014 
NSAID-induced small intestinal injury
 08 July 2014 
Drug-induced liver injury
 07 July 2014 
Pediatric celiac disease risk factors
 07 July 2014 
Obesity and complications after lapaproscopic colorectal surgery
 07 July 2014 
Everolimus and advanced hepatocellular carcinoma
 04 July 2014 
Day-case vs inpatient laparoscopic fundoplication
 04 July 2014 
Alcohol assessment in liver transplant
 04 July 2014 
Clinical competence in colorectal cancer surgery
 03 July 2014 
Predicting acute liver failure in drug-induced liver injury
 03 July 2014 
Cognitive dysfunction impairs quality of life after liver transplant
 03 July 2014 
NOTES for colon resections
 02 July 2014 
Routine colonoscopy for uncomplicated diverticulitis
 02 July 2014 
Risk of stroke in ulcerative colitis
 02 July 2014 
Hemodialysis during liver transplant
 01 July 2014 
Outcomes for pregnant women with primary biliary cirrhosis
 01 July 2014 
Liver-prognosis assessment in Hep C
 01 July 2014 
Mortality from biliary diseases requiring ERCP
 30 June 2014 
Combination therapy for eradication of Helicobacter pylori
 30 June 2014 
Drug-induced liver injury
 30 June 2014 
Surrogate for adenoma detection rate
 27 June 2014 
Infliximab and luminal pediatric Crohn's
 27 June 2014 
Colonoscopy surveillance intervals
 27 June 2014 
Endoscopy protocol for serrated polyposis syndrome
 26 June 2014 
Cognitive impairment in celiac disease
 26 June 2014 

Congenital malformations in offspring of parents with celiac disease

 26 June 2014 
Risk of colorectal adenomas and glucose metabolism

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us